AURA
insider transactionsAura Biosciences, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-7.1M
0 buy · 7.1M sell
Net value · 365d
-$39.8M
$0 in · $39.8M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
10
0 buy · 7.1M sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Anthony S Gibney KEY
Chief Financial and Business …
$82.3K
12.8K sh · $6.42
Own -5%
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Director
$0
15.0K sh
Own +71%
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Director
$0
15.0K sh
Own +64%
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Director
$0
15.0K sh
Own +8%
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Director
$0
15.0K sh
Own +64%
-
Grant·A
Chief Executive Officer and P…
$0
2.2M sh
Own New
-
Grant·A
Chief Executive Officer and P…
$0
553.8K sh
Own +92%
-
Grant·A
Chief Executive Officer and P…
$0
600.1K sh
Own New
-
Sell·S
$39.0M
6.9M sh · $5.64
Own -100%
-
Sell·S
Chief Legal Officer and Secre…
$82.4K
11.7K sh · $7.02
Own -5%
-
Grant·A
Chief Legal Officer and Secre…
$0
112.7K sh
Own New
-
Grant·A
Chief Legal Officer and Secre…
$0
62.3K sh
Own +37%
-
Grant·A
Anthony S Gibney KEY
Chief Financial and Business …
$0
128.8K sh
Own New
-
Grant·A
Anthony S Gibney KEY
Chief Financial and Business …
$0
71.2K sh
Own +34%
-
Grant·A
President and Chief Executive…
$0
249.0K sh
Own New
-
Grant·A
President and Chief Executive…
$0
166.0K sh
Own +41%
-
Grant·A
Chief Technology Officer
$0
112.7K sh
Own New
-
Grant·A
Chief Technology Officer
$0
62.3K sh
Own +34%
-
Grant·A
Chief Medical Officer
$0
160.9K sh
Own New
-
Grant·A
Chief Medical Officer
$0
89.1K sh
Own +38%
-
Grant·A
Amy Elazzouzi KEY
Senior Vice President, Finance
$0
80.5K sh
Own New
-
Grant·A
Amy Elazzouzi KEY
Senior Vice President, Finance
$0
44.5K sh
Own +59%
-
Sell·S
Chief Legal Officer and Secre…
$61.0K
12.1K sh · $5.05
Own -7%
-
Sell·S
Chief Technology Officer
$80.2K
15.9K sh · $5.05
Own -8%
-
Sell·S
Chief Medical Officer
$103.2K
20.4K sh · $5.06
Own -8%
-
Sell·S
Amy Elazzouzi KEY
Senior Vice President, Finance
$43.3K
8.5K sh · $5.06
Own -10%
-
Sell·S
President and Chief Executive…
$241.1K
47.6K sh · $5.06
Own -10%
-
Sell·S
Amy Elazzouzi KEY
Senior Vice President, Finance
$7.7K
1.6K sh · $4.86
Own -2%
-
Sell·S
President and Chief Executive…
$82.3K
16.9K sh · $4.86
Own -4%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 16, 2026 | Anthony S Gibney KEY | Sell S | 12.8K | $82.3K |
| Jun 11, 2026 | Teresa Marie Bitetti | Grant A | 30.0K | $0 |
| Jun 11, 2026 | Teresa Marie Bitetti | Grant A | 15.0K | $0 |
| Jun 11, 2026 | Sapna Srivastava | Grant A | 30.0K | $0 |
| Jun 11, 2026 | Sapna Srivastava | Grant A | 15.0K | $0 |
| Jun 11, 2026 | David Michael Johnson | Grant A | 30.0K | $0 |
| Jun 11, 2026 | David Michael Johnson | Grant A | 15.0K | $0 |
| Jun 11, 2026 | Antony C. Mattessich | Grant A | 30.0K | $0 |
| Jun 11, 2026 | Antony C. Mattessich | Grant A | 15.0K | $0 |
| May 19, 2026 | Natalie C. Holles KEY | Grant A | 2.2M | $0 |
| May 19, 2026 | Natalie C. Holles KEY | Grant A | 553.8K | $0 |
| May 19, 2026 | Natalie C. Holles KEY | Grant A | 600.1K | $0 |
| May 7, 2026 | Matrix Capital Management Company, LP / David E. Goel | Sell S | 6.9M | $39.0M |
| Apr 16, 2026 | Conor Kilroy | Sell S | 11.7K | $82.4K |
| Mar 2, 2026 | Conor Kilroy | Grant A | 112.7K | $0 |
| Mar 2, 2026 | Conor Kilroy | Grant A | 62.3K | $0 |
| Mar 2, 2026 | Anthony S Gibney KEY | Grant A | 128.8K | $0 |
| Mar 2, 2026 | Anthony S Gibney KEY | Grant A | 71.2K | $0 |
| Mar 2, 2026 | Pinos Elisabet De Los KEY | Grant A | 249.0K | $0 |
| Mar 2, 2026 | Pinos Elisabet De Los KEY | Grant A | 166.0K | $0 |
| Mar 2, 2026 | Mark Plavsic | Grant A | 112.7K | $0 |
| Mar 2, 2026 | Mark Plavsic | Grant A | 62.3K | $0 |
| Mar 2, 2026 | Janet Jill Hopkins | Grant A | 160.9K | $0 |
| Mar 2, 2026 | Janet Jill Hopkins | Grant A | 89.1K | $0 |
| Mar 2, 2026 | Amy Elazzouzi KEY | Grant A | 80.5K | $0 |
| Mar 2, 2026 | Amy Elazzouzi KEY | Grant A | 44.5K | $0 |
| Feb 17, 2026 | Conor Kilroy | Sell S | 12.1K | $61.0K |
| Feb 17, 2026 | Mark Plavsic | Sell S | 15.9K | $80.2K |
| Feb 17, 2026 | Janet Jill Hopkins | Sell S | 20.4K | $103.2K |
| Feb 17, 2026 | Amy Elazzouzi KEY | Sell S | 8.5K | $43.3K |
| Feb 17, 2026 | Pinos Elisabet De Los KEY | Sell S | 47.6K | $241.1K |
| Jan 20, 2026 | Amy Elazzouzi KEY | Sell S | 1.6K | $7.7K |
| Jan 20, 2026 | Pinos Elisabet De Los KEY | Sell S | 16.9K | $82.3K |
About AURA insider trading
This page tracks insider transactions for Aura Biosciences, Inc. (AURA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.